Appendix 4E and Annual Report
BRISBANE & MELBOURNE, 27 August, 2019
Anatara Lifesciences today released its Appendix 4E and review of operations for the period ending 30th June 2019.
Key points:
- Income during period was $1,683,479, resulting from recognition of Detach® deferred licensing income, R&D tax incentive refund and finance income
- Anatara remains funded until the anticipated partnering of its first human gastrointestinal product, GaRP (Gastrointestinal ReProgramming) dietary supplement, in the second half of calendar 2020
- Detailed development plans announced for GaRP dietary supplement in July 2018
- Board renewal with appointment of experienced human health Board members Sue MacLeman, Dr Jane Ryan and Dr David Brookes
- Product Development Advisory Board with world-leading scientists and clinicians formed in October 2018
- Australian Pesticides and Veterinary Medicines Authority (APVMA) approval for Detach® to aid in the control of scour in piglets in October 2018
- Appointment of Steven Lydeamore as CEO in December 2018
- Successful GaRP proof of concept studies demonstrating significant reduction inflammation thereby restoring gut integrity in February 2019
- Anatara regained global rights to Detach® in June 2019
- Advisory meeting held with external animal health experts in August 2019 informing strategy for partnering Detach® in 2020
Please click here to view the ASX announcement.
|
